Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Seipel

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Cancers|September 22, 2018
Autologous Transplantation for Older Adults with AMLBeatrice U Mueller, Katja Seipel, Ulrike Bacher, et al.
Biochimica Et Biophysica Acta|July 12, 2015
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin geneJulian A Schardt, Manuela Keller, Katja Seipel, et al.
Current Oncology (Toronto, Ont.)|August 27, 2025
Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell TherapyKatja Seipel, Inna Shaforostova, Henning Nilius, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|June 10, 2004
Basic leucine zipper transcription factors C/EBP and MafL in the hydrozoan jellyfish Podocoryne carneaKatja Seipel, Nathalie Yanze, Peter Müller, et al.
International Journal of Molecular Sciences|August 7, 2021
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid LeukemiaKatja Seipel, Carolyn Graber, Laura Flückiger, et al.
International Journal of Molecular Sciences|October 27, 2022
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid LeukemiaKatja Seipel, Yvo Brügger, Harpreet Mandhair, et al.
Leukemia Research|January 14, 2020
MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantationKatja Seipel, Christian Messerli, Gertrud Wiedemann, et al.
Cancers|October 6, 2020
(2<i>R</i>,3<i>S</i>)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid LeukemiaJeffrey R Idle, Katja Seipel, Ulrike Bacher, et al.
Cancers|March 28, 2026
Disease Stage-Dependent Clinical Impact of <i>CTLA4</i> Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell TransplantationPinar Horum, Katja Seipel, Inna Shaforostova, et al.
BJC Reports|September 22, 2025
Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literatureChristian Rausch, Ulrike Bacher, Joelle Tchinda, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Cancers|September 22, 2018
Autologous Transplantation for Older Adults with AMLBeatrice U Mueller, Katja Seipel, Ulrike Bacher, et al.
Biochimica Et Biophysica Acta|July 12, 2015
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin geneJulian A Schardt, Manuela Keller, Katja Seipel, et al.
Current Oncology (Toronto, Ont.)|August 27, 2025
Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell TherapyKatja Seipel, Inna Shaforostova, Henning Nilius, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|June 10, 2004
Basic leucine zipper transcription factors C/EBP and MafL in the hydrozoan jellyfish Podocoryne carneaKatja Seipel, Nathalie Yanze, Peter Müller, et al.
International Journal of Molecular Sciences|August 7, 2021
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid LeukemiaKatja Seipel, Carolyn Graber, Laura Flückiger, et al.
International Journal of Molecular Sciences|October 27, 2022
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid LeukemiaKatja Seipel, Yvo Brügger, Harpreet Mandhair, et al.
Leukemia Research|January 14, 2020
MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantationKatja Seipel, Christian Messerli, Gertrud Wiedemann, et al.
Cancers|October 6, 2020
(2<i>R</i>,3<i>S</i>)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid LeukemiaJeffrey R Idle, Katja Seipel, Ulrike Bacher, et al.
Cancers|March 28, 2026
Disease Stage-Dependent Clinical Impact of <i>CTLA4</i> Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell TransplantationPinar Horum, Katja Seipel, Inna Shaforostova, et al.
BJC Reports|September 22, 2025
Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literatureChristian Rausch, Ulrike Bacher, Joelle Tchinda, et al.
Pageof 8